Clinical Trial Update: Real World Study of Effectiveness of Sunitinib or Sorafenib to Chinese Unresectable Locally Advanced or Metastatic PRCC

View source ↗

Summary

A real-world study in China evaluating the effectiveness of sunitinib or sorafenib for unresectable, locally advanced or metastatic papillary renal cell carcino…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Papillary Renal Cell Carcinoma

Drugs mentioned

• Nexavar (Sorafenib)
• Sutent (sunitinib)

Snippet

Sponsor: AstraZeneca | Conditions: Papillary Renal Cell Carcinoma | Status: RECRUITING